The Endocrine and metabolic committee of the FDA recommended 13-7 to approve the first weight loss drug since 1999. Contrave (a combination of bupropion and naltrexone) was recommended for approval and while the FDA usually follows the vote of its expert committees, it is not bound to do so.
If the FDA moves to follow the advice of its experts, the 4 trials which show roughly a 5-10% weight loss will have worked. Contrave is not a magic bullet, yet offers great hope as nearly 66% of us are overweight. Full labeling and details are available at www.fda.gov